-

Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS® ▼in the European Economic Area, the United Kingdom, Australia and Brazil

LONDON--(BUSINESS WIRE)--Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an exclusive licensing agreement with Radius Health, Inc., for the rights to commercialise ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures.

Theramex will commercialise and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingdom, Australia and Brazil.

“Theramex has again shown its commitment to women and the care and good management of bone health, by adding this important product to our Osteoporosis franchise. We are delighted to be entering into this partnership with Radius, building on our expanding portfolio and aligning missions to reduce fracture risks for many postmenopausal women suffering from osteoporosis.” - Rob Stewart, CEO of Theramex

“We are thrilled to have Theramex bring abaloparatide to postmenopausal women in Europe who could benefit from this impactful treatment. Our aligned, strategic vision of bringing effective solutions to the right patient gives us unwavering confidence in this partnership. We look forward to seeing the continued global expansion of abaloparatide to patients with osteoporosis worldwide.” - Scott Briggs, CEO of Radius

About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. Theramex supports women at different stages of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause, and osteoporosis. Theramex’s commitment is to listen to and understand its patients, serve their needs and offer healthcare solutions to help improve their lives. Theramex’s vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through different stages of their life.
www.theramex.com

About Radius
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 for the treatment of men with osteoporosis at high risk for fracture.
ELADYNOS®(abaloparatide) injection was approved by the European Medicines Agency for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapies. This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines.
www.radiuspharm.com

FOR MEDIA AND INVESTORS ONLY
ELAD_HQ_PRESSR_009443  D.O.P 8/3/23

Contacts

For further information about Theramex, please contact:
Katja Lundell, Senior Director, Global Head of Policy, Pricing and Communications.
Email: Katja.Lundell@Theramex.com
Phone : +44 203 962 5555

For further information about Radius please contact:
Sara Goldberg: Lead, Communications
Email: corporatecommunications@radiuspharm.com
Phone: +1 631 379 8374

Industry:

Theramex

Release Versions
EnglishSpanish (Summary)PortugueseGermanFrenchItalian (Summary)Dutch (Summary)

Contacts

For further information about Theramex, please contact:
Katja Lundell, Senior Director, Global Head of Policy, Pricing and Communications.
Email: Katja.Lundell@Theramex.com
Phone : +44 203 962 5555

For further information about Radius please contact:
Sara Goldberg: Lead, Communications
Email: corporatecommunications@radiuspharm.com
Phone: +1 631 379 8374

Social Media Profiles
Theramex Global
More News From Theramex

Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.

LONDON--(BUSINESS WIRE)--Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc. Viatris retains the rights for Australia and Japan. The transaction is subject to customary regulatory and anti-trust approvals. “As we continue to strengthen our commitment to women’s health and improve our patients access to high quality treatm...

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Symptoms of Uterine Fibroids

LONDON--(BUSINESS WIRE)--The European Commission (EC) has granted Marketing Authorization for Yselty® (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age. This announcement is in partnership with ObsEva SA (Nasdaq: OBSV), a biopharmaceutical company developing and commercializing novel therapies for women’s health. The EC decision follows the Committee for Medicinal P...

Theramex Launches Non-hormonal Femarelle® on the 12th of May

LONDON--(BUSINESS WIRE)--Theramex will be joining the 20th International Society of Gynecological Endocrinology (ISGE) congress from the 11th-14th May in Florence, Italy. The ISGE is a non-profit organization whose purpose is to drive more awareness around important gynecology topics ensuring a dialogue between interested parties. Theramex are very proud to introduce Femarelle® which Theramex will commercialize in Italy, France, Spain, Germany, UK, Belgium, Poland and Australia. Femarelle® is a...
Back to Newsroom